 Manja Zec
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatty Acid Desaturases | 3 | 2021 | 32 | 1.980 |
Why?
| | Fatty Acids | 10 | 2021 | 443 | 1.880 |
Why?
| | Phospholipids | 6 | 2021 | 223 | 1.220 |
Why?
| | Juglans | 6 | 2025 | 7 | 1.180 |
Why?
| | Zinc | 5 | 2019 | 297 | 1.080 |
Why?
| | Polyphenols | 4 | 2021 | 17 | 1.030 |
Why?
| | Semicarbazones | 3 | 2014 | 3 | 0.930 |
Why?
| | Coordination Complexes | 2 | 2014 | 13 | 0.820 |
Why?
| | Selenium Compounds | 2 | 2014 | 21 | 0.820 |
Why?
| | Vitamin D | 3 | 2024 | 397 | 0.790 |
Why?
| | Overweight | 4 | 2023 | 558 | 0.760 |
Why?
| | Photinia | 5 | 2021 | 5 | 0.750 |
Why?
| | Vitamin D Deficiency | 2 | 2019 | 186 | 0.680 |
Why?
| | Arachidonic Acid | 1 | 2020 | 120 | 0.670 |
Why?
| | Recommended Dietary Allowances | 1 | 2019 | 18 | 0.640 |
Why?
| | Plasma | 1 | 2021 | 212 | 0.610 |
Why?
| | Dyslipidemias | 1 | 2019 | 176 | 0.570 |
Why?
| | Metabolic Syndrome | 4 | 2023 | 354 | 0.540 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2111 | 0.530 |
Why?
| | Erythrocytes | 2 | 2019 | 700 | 0.510 |
Why?
| | Nuts | 4 | 2025 | 12 | 0.500 |
Why?
| | Nickel | 2 | 2014 | 62 | 0.490 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2129 | 0.470 |
Why?
| | Diet | 8 | 2025 | 1278 | 0.460 |
Why?
| | Biomarkers | 4 | 2019 | 4149 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2189 | 0.390 |
Why?
| | Dietary Supplements | 3 | 2024 | 561 | 0.380 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2025 | 140 | 0.370 |
Why?
| | Fructose | 5 | 2023 | 112 | 0.350 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 658 | 0.320 |
Why?
| | Linoleic Acid | 2 | 2019 | 43 | 0.290 |
Why?
| | Eating | 2 | 2021 | 380 | 0.280 |
Why?
| | Cadmium | 3 | 2014 | 69 | 0.280 |
Why?
| | Cross-Sectional Studies | 6 | 2020 | 5472 | 0.270 |
Why?
| | Blood Pressure | 4 | 2025 | 1786 | 0.270 |
Why?
| | Dietary Fats | 2 | 2019 | 304 | 0.260 |
Why?
| | Genotype | 2 | 2021 | 1916 | 0.240 |
Why?
| | Serbia | 3 | 2019 | 7 | 0.240 |
Why?
| | Diet, Mediterranean | 2 | 2022 | 30 | 0.230 |
Why?
| | Fruit and Vegetable Juices | 3 | 2020 | 15 | 0.210 |
Why?
| | Cardiovascular System | 1 | 2025 | 137 | 0.210 |
Why?
| | Obesity | 4 | 2023 | 2992 | 0.210 |
Why?
| | Dietary Fats, Unsaturated | 2 | 2020 | 23 | 0.210 |
Why?
| | Obesity, Metabolically Benign | 1 | 2023 | 4 | 0.210 |
Why?
| | Plant Extracts | 3 | 2020 | 202 | 0.210 |
Why?
| | Middle Aged | 14 | 2024 | 33479 | 0.200 |
Why?
| | Feeding Behavior | 2 | 2019 | 654 | 0.200 |
Why?
| | Hypertension | 2 | 2023 | 1295 | 0.200 |
Why?
| | HeLa Cells | 3 | 2014 | 636 | 0.200 |
Why?
| | Adult | 12 | 2024 | 37929 | 0.200 |
Why?
| | Nutritional Status | 3 | 2019 | 350 | 0.190 |
Why?
| | Group II Phospholipases A2 | 1 | 2021 | 9 | 0.190 |
Why?
| | Glucose Transporter Type 3 | 1 | 2021 | 13 | 0.180 |
Why?
| | Glucose Transporter Type 2 | 1 | 2021 | 15 | 0.180 |
Why?
| | Sirtuin 1 | 1 | 2021 | 30 | 0.180 |
Why?
| | Gallic Acid | 1 | 2021 | 13 | 0.180 |
Why?
| | Life Style | 2 | 2023 | 490 | 0.180 |
Why?
| | Catalase | 1 | 2021 | 130 | 0.180 |
Why?
| | Glucose Transporter Type 1 | 1 | 2021 | 50 | 0.170 |
Why?
| | Female | 17 | 2024 | 73304 | 0.170 |
Why?
| | Energy Intake | 3 | 2020 | 485 | 0.170 |
Why?
| | Eicosapentaenoic Acid | 1 | 2021 | 39 | 0.170 |
Why?
| | Humans | 27 | 2025 | 137585 | 0.170 |
Why?
| | KATP Channels | 1 | 2020 | 20 | 0.170 |
Why?
| | Hypothalamus | 1 | 2021 | 153 | 0.170 |
Why?
| | gamma-Linolenic Acid | 1 | 2019 | 2 | 0.170 |
Why?
| | Libya | 1 | 2019 | 1 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2020 | 99 | 0.160 |
Why?
| | Cholesterol | 2 | 2019 | 410 | 0.160 |
Why?
| | Transients and Migrants | 1 | 2019 | 24 | 0.160 |
Why?
| | Male | 16 | 2024 | 67762 | 0.160 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2019 | 48 | 0.160 |
Why?
| | Calcium Channels | 1 | 2020 | 159 | 0.160 |
Why?
| | Magnesium | 1 | 2019 | 156 | 0.160 |
Why?
| | Cell Line, Tumor | 5 | 2014 | 3412 | 0.160 |
Why?
| | Copper | 1 | 2019 | 104 | 0.150 |
Why?
| | Sunlight | 1 | 2019 | 73 | 0.150 |
Why?
| | Body Weight | 2 | 2021 | 985 | 0.150 |
Why?
| | Metabolic Diseases | 1 | 2019 | 108 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 437 | 0.140 |
Why?
| | Neoplasms | 3 | 2022 | 2671 | 0.140 |
Why?
| | Alleles | 1 | 2021 | 891 | 0.140 |
Why?
| | Iron | 1 | 2019 | 313 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 558 | 0.140 |
Why?
| | Heart | 1 | 2021 | 655 | 0.130 |
Why?
| | Pyridines | 2 | 2011 | 506 | 0.130 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2016 | 6 | 0.130 |
Why?
| | Membrane Lipids | 2 | 2014 | 91 | 0.130 |
Why?
| | Placebos | 1 | 2017 | 199 | 0.130 |
Why?
| | Cytochromes c | 2 | 2014 | 60 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 383 | 0.130 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 35 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 697 | 0.130 |
Why?
| | Rats | 5 | 2023 | 5647 | 0.120 |
Why?
| | Apoptosis | 4 | 2012 | 2553 | 0.120 |
Why?
| | Hippocampus | 1 | 2021 | 895 | 0.120 |
Why?
| | Cause of Death | 1 | 2018 | 434 | 0.120 |
Why?
| | Caspase 3 | 2 | 2014 | 246 | 0.120 |
Why?
| | Cell Cycle | 3 | 2014 | 601 | 0.120 |
Why?
| | Rats, Wistar | 3 | 2021 | 455 | 0.120 |
Why?
| | Mannans | 1 | 2014 | 6 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2016 | 180 | 0.120 |
Why?
| | Taste | 1 | 2017 | 229 | 0.110 |
Why?
| | Obesity, Abdominal | 1 | 2014 | 48 | 0.110 |
Why?
| | Beverages | 1 | 2014 | 69 | 0.110 |
Why?
| | Adiposity | 1 | 2019 | 518 | 0.110 |
Why?
| | Cations, Divalent | 1 | 2014 | 52 | 0.110 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 90 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.100 |
Why?
| | Organ Specificity | 1 | 2014 | 305 | 0.100 |
Why?
| | Necrosis | 1 | 2014 | 246 | 0.100 |
Why?
| | Incidence | 1 | 2019 | 2804 | 0.100 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2012 | 56 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 429 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2012 | 132 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2020 | 2833 | 0.090 |
Why?
| | Breast | 1 | 2012 | 151 | 0.090 |
Why?
| | Intercalating Agents | 1 | 2011 | 5 | 0.090 |
Why?
| | Malonates | 1 | 2011 | 8 | 0.090 |
Why?
| | Animals | 9 | 2025 | 36940 | 0.090 |
Why?
| | Cobalt | 1 | 2011 | 52 | 0.090 |
Why?
| | Azides | 1 | 2011 | 46 | 0.090 |
Why?
| | Selenium | 1 | 2011 | 43 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 229 | 0.090 |
Why?
| | Antioxidants | 1 | 2014 | 584 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 622 | 0.090 |
Why?
| | Cell Survival | 1 | 2014 | 1120 | 0.080 |
Why?
| | Organoselenium Compounds | 1 | 2010 | 11 | 0.080 |
Why?
| | Metals | 1 | 2011 | 136 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2236 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2253 | 0.080 |
Why?
| | Risk Factors | 5 | 2023 | 10388 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1276 | 0.080 |
Why?
| | South Africa | 2 | 2019 | 222 | 0.080 |
Why?
| | Gene Expression | 1 | 2014 | 1502 | 0.070 |
Why?
| | Cell Movement | 1 | 2012 | 967 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2024 | 1993 | 0.070 |
Why?
| | Aged | 4 | 2021 | 23961 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2847 | 0.070 |
Why?
| | Phytotherapy | 2 | 2019 | 83 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2011 | 1096 | 0.060 |
Why?
| | Mitochondria | 1 | 2011 | 948 | 0.060 |
Why?
| | Cholecalciferol | 1 | 2024 | 60 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2024 | 199 | 0.050 |
Why?
| | Cations | 1 | 2023 | 84 | 0.050 |
Why?
| | PPAR alpha | 1 | 2022 | 58 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2389 | 0.040 |
Why?
| | Feces | 1 | 2024 | 484 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2023 | 491 | 0.040 |
Why?
| | Sodium-Calcium Exchanger | 1 | 2020 | 16 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2021 | 686 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 132 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2019 | 39 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 374 | 0.040 |
Why?
| | Waist Circumference | 1 | 2019 | 143 | 0.040 |
Why?
| | Fruit | 1 | 2019 | 140 | 0.040 |
Why?
| | Mice | 2 | 2012 | 17787 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2011 | 611 | 0.040 |
Why?
| | Bacteria | 1 | 2024 | 858 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 496 | 0.030 |
Why?
| | Centralized Hospital Services | 1 | 2016 | 6 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 90 | 0.030 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2016 | 30 | 0.030 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2016 | 36 | 0.030 |
Why?
| | Platelet Activation | 1 | 2017 | 93 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 103 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7604 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2018 | 266 | 0.030 |
Why?
| | Alanine Transaminase | 1 | 2017 | 157 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.030 |
Why?
| | Homozygote | 1 | 2016 | 203 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1020 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1759 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 293 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 346 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 399 | 0.030 |
Why?
| | Gene Frequency | 1 | 2016 | 521 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 267 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 915 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1153 | 0.030 |
Why?
| | Creatinine | 1 | 2017 | 499 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1266 | 0.030 |
Why?
| | Triglycerides | 1 | 2017 | 524 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3196 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 971 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2828 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 660 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2016 | 614 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2475 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3556 | 0.020 |
Why?
| | Artemia | 1 | 2011 | 8 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2011 | 149 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 91 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 168 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2011 | 284 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2035 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7635 | 0.020 |
Why?
| | Molecular Structure | 1 | 2010 | 489 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1226 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 476 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5742 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 13209 | 0.020 |
Why?
| | Kinetics | 1 | 2011 | 1670 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5079 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6828 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 3958 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1459 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 21513 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10811 | 0.010 |
Why?
| | Child | 1 | 2021 | 21935 | 0.010 |
Why?
| | United States | 1 | 2018 | 14841 | 0.010 |
Why?
|
|
Zec's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|